Related Experiment Video
Updated: Aug 24, 2026
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
A potential antitumor peptide therapeutic derived from antineoplastic urinary protein
Kathleen M Hehir1, Alexander Baguisi, Sarah E Pennington
1TranXenoGen Inc., Technology Development, 800 Boston Turnpike, Shrewsbury, MA 01545, USA. khehir@tranxenogen.com
Abstract:
New therapies in cancer treatment are focusing on multifaceted approaches to starve and kill tumors utilizing both antiangiogenic and chemotherapeutic compounds. Antineoplastic Urinary Protein (ANUP), a 32k Da protein normally secreted in human urine, has been previously described as a molecule possessing both antiproliferative and antiangiogenic activities. Two synthetic peptides complimentary to the N-terminus of ANUP were designed to test their ability to reproduce these beneficial effects but ultimately to provide a more useful small molecule therapeutic. The results show that the peptides reduced tumor burden by up to 70% in a nude mouse model and demonstrated the ability to inhibit blood vessel formation in a chick chorioallantoic membrane assay (CAM).
Insights
New synthetic peptides mimic Antineoplastic Urinary Protein (ANUP) to fight cancer. These small molecules significantly reduced tumor size and inhibited blood vessel formation in preclinical models.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Novel cancer therapies integrate antiangiogenic and chemotherapeutic strategies to inhibit tumor growth.
- Antineoplastic Urinary Protein (ANUP), a urinary protein, exhibits antiproliferative and antiangiogenic properties.
- Developing small molecule therapeutics based on ANUP's activity is a promising approach.
Purpose of the Study:
- To design and evaluate synthetic peptides mimicking ANUP's N-terminus.
- To assess the therapeutic potential of these peptides in cancer treatment.
- To determine if peptides can replicate ANUP's antiproliferative and antiangiogenic effects.
Main Methods:
- Design of two synthetic peptides complementary to the ANUP N-terminus.
- In vivo efficacy testing using a nude mouse tumor model.
- In vitro antiangiogenic assessment via chick chorioallantoic membrane (CAM) assay.
Main Results:
- Synthetic peptides demonstrated significant tumor burden reduction (up to 70%) in mice.
- Peptides effectively inhibited new blood vessel formation in the CAM assay.
- The results validate the antiproliferative and antiangiogenic potential of ANUP-derived peptides.
Conclusions:
- Synthetic peptides derived from ANUP show promise as novel small molecule cancer therapeutics.
- These peptides possess both direct tumor-killing and antiangiogenic capabilities.
- Further development could lead to effective treatments for various cancers.
